Advances from genetic clues in pancreatic cancer

Current Opinion in Oncology

Volumn 10, Issue 1, 1998, Pages 74-80

  Kern, Scott E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER GROWTH; COLORECTAL CANCER; CYTOGENETICS; FAMILIAL CANCER; GENE MUTATION; HUMAN; HUMAN CELL; INHERITANCE; MOLECULAR GENETICS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW;

EID: 0031974859     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199801000-00012     Document Type: Review

References (69)

1. Rozenblum E, Schutte M, Goggins M, Hahn SA, Lu J, Panzer S, Zahurak M, Goodman SN, Hruban RH, Yeo CJ, Kern SE: Natural relationships among tumor-suppressive pathways: application of pancreatic cancer model. Cancer Res 1997, 57:1731-1734.
2. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
3. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995, 270:6221-6226.
4. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of Inactive Ras-Raf complexes. J Biol Chem 1995, 270:26802-26806.
5. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
6. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-31.
7. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1 994, 265:415-416.
8. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al.: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995, 11:210-212.
9. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, et al.: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-3130.
10. Huang L, Lang D, Geradts J, Obara T, Klein-Szanto AJ, Lynch HT, Ruggeri BA: Molecular and Immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol Carcinog 1996, 15:85-95.
11. Pellegata S, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN: K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994, 54:1556-1560.
12. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-3033.
13. Hahn SA, Hoque ATMS, Moskaluk CA, daCosta LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, et al.: Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996, 56:490-494.
14. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992, 256:827-830.
15. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 1991, 252:1708-1711.
16. Friedman PN, Chen X, Bargonetti J, Prives C: The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A 1993, 90:3319-3323, [published erratum appears in Proc Natl Acad Sci U S A 1993, 90:5878]
17. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, et al.: DPC4, a candidate tumor-suppressor gene at 18q21.1. Science 1996 271:350-353.
18. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM: Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995, 139:1347-1358.
19. Savage C, Das P, Finelli AL, Twonsend SR, Sun C-Y, Baird SE, Padgett RW: Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci U S A 1996, 93:790-794.
20. Kim J, Johnson K, Chen HJ, Carroll S, Laughton A: Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 1997, 388:304-308.
21. Liu F, Hata A, Baker JC, Doody J, Carcamo J, Harland RM, Massague J: A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 1996, 381:620-623.
22. Hata A, Lo RS, Wotton D, Lagna G, Massague J: Mutations increasing autoinhibition inactivate tumor suppressors Smad2 and Smad4. Nature 1997, 388:82-87.
23. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J: Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996, 383:832-836.
24. Zhang Y, Feng X, We R, Derynck R: Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 1996, 383:168-172.
25. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Buchler MW, Korc M: Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996, 67:283-288.
26. Schutte M, Hruban RH, Hedrick L, Molnar'Nadasdy G, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawro H, Sidransky D, et al.: DPC4 in various tumor types. Cancer Res 1996, 56:2527-2530.
27. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yee CJ, Kern SE: Allelotype of pancreatic adenocarcinoma. Cancer Res 1994, 54:2761-2764.
28. Hahn SA, Seymour AB, Hoque ATMS, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, et al.: Allelotype of pancreatic adenocarcinoma using a xenograft model. Cancer Res 1995, 55:4670-4675.
29. Brat DJ, Hahn SA, Griffin CA, Yeo CJ, Kern SE, Hruban RH: The structural basis of molecular genetic deletions. An integration of classical cytogenetlc and molecular analyses in pancreatic adenocarcinoma. Am J Pathol 1997, 150:383-391.
30. Miwa W, Yasuda J, Murakami Y, Yashima K, Sugano K, Sekine T, Kono A, Egawa S, Yamaguchi K, Hayashizaki Y, et al.: Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996, 225:968-974.
31. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Atomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cancer cells and Inhibition of AKT2 expression and tumorigenecity by antisense RNA. Proc Natl Acad Sci U S A 1996, 93:3636-3641.
32. Batra SK, Metzgar RS, Hollingsworth MA: Molecular cloning and sequence analysis of the human ribosomal protein S16. J Biol Chem 1991, 266:6830-6833.
33. Solinas-Toldo S, Wallrapp C, Muller-Pillasch F, Bentz M, Gress T, Lichter P: Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res 1996, 56:3803-3807.
34. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, Lichter P, Friess H, Buchler M, Fink T, Adler G, Gress TM: Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res 1997, 57:3135-3139.
35. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J, Lynch JF: Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990, 85:54-60.
36. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WHJ, et al.: Increased risk of pancreatic cancer in melanoma-prone kindreds with P16INK4 mutations. N Engl J Med 1995, 333:970-974.
37. Lynch HT, Fusaro RM: Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991, 6:127-131.
38. Whelan AJ, Bartsch D, Goodfellow PJ: Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995, 333:975-977.
39. Moskaluk CA, Hruban RH, Lietman AS, Smyrk T, Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT, et al.: Novel germline p16INK4a mutation in familial pancreatic carcinoma. Hum Mutat 1998, in press.
40. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Hoque ATMS, Rozenblum E, Weinstein CL, Bittner M, Meltzer PS, Trent JM, et al.: A homozygous deletion identified by representational difference analysis in pancreatic carcinoma overlaps the BRCA2 region. Proc Natl Acad Sci U S A 1995, 92:5950-5954.
41. Schutte M, Rozenblum E, Moskaluk CA, Guan X, Hoque ATMS, Hahn SA, da Costa LT, de Jong PJ, Kern SE: An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12-13. Cancer Res 1995, 55:4570-4574.
42. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ögmundsdottir HM, EyfjÖrd JE: A single BRCA2 mutation in male and female breast carcinoma families from Iceland with varied cancer phenotypes. Nat Genet 1996, 13:117-119.
43. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH, et al.: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-5364.
44. Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, et al.: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients [letter]. Nat Genet 1997, 16:17-18.
45. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF: Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985, 52:271-273.
46. Risch N, Menkangas K: The future of genetic studies of complex human diseases. Science 1996, 273:1517-1519.
47. Adami JG: Principles of Pathology, edn 2. New York: Lea and Febiger; 1910:843-847.
48. Fisher JC, Hollomon JH: A hypothesis for the origin of cancer foci. Cancer 1951, 4:916-921.
49. Nordling CO: A new theory on the cancer-inducing mechanism. Br J Cancer 1953, 7:68-73.
50. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
51. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
52. Smith KJ, Johnson KA, Bryan TM, Hill DE, Markowitz S, Willson JKV, Paraskeva C, Petersen GM, Hamilton SR, Vogelstein B, et al.: The APC gene product in normal and tumor cells. Proc Natl Acad Sci U S A 1993, 90:2846-2850.
53. Yashima K, Nakamori S, Murakami Y, Yamaguchi A, Hayashi K, Ishikawa O, Konishi Y, Sekiya T: Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers. Int J Cancer 1994, 59:43-47.
54. McKie AB, Filipe MI, Lemoine NR: Abnormalities affecting the APC and MCC tumour suppressor gene loci on chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer 1993, 55:598-603.
55. Goggins M, Hilgers W, Hruban RH, Kern SE: Normal beta-catenin gene in pancreatic cancer, NOGO 1997, 1:4.
56. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz SD, Hamilton SR, Kern SE, et al.: Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996, 13:343-346.
57. Kozuka S, Sassa R, Taki T, Masamoto K, Nagasawa S, Saga S, Hasegawa K, Takeuchi M: Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979, 43:1 418-1428.
58. Cubilla AL, Fitzgerald PJ: Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 1976, 36:2690-2698.
59. Furukawa T, Chiba R, Kobari M, Matsuno S, Nagura H, Takahashi T: Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen. Arch Pathol Lab Med 1994, 118:227-234.
60. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y: Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993, 53:953-956.
61. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994, 54:3568-3573.
62. Moskaluk CA, Hruban RH, Kern SE: p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997, 57:2140-2143.
63. Tada M, Omata M, Kawai S, et al.: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993, 53:2472-2474.
64. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K, Shay JW, Matsuura Y, Yokoyama T: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997, 57:326-331.
65. van Es, JM, Polak MM, van den Berg FM, Ramsoekh TB, Craanen ME, Hruban RH, Offerhaus GJ: Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 1995, 48:218-222.
66. Sorenson GD, Pribish DM, Valone FH, et al.: Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994, 3:67-71.
67. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
68. Kyo S, Takakura M, Kohama T, Inoue M: Telomerase activity in human endometrium. Cancer Res 1997, 57:610-613.
69. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 1997, 276:1268-1272.